

**TNFRSF11B antibody - N-terminal region**  
**Rabbit Polyclonal Antibody**  
**Catalog # AI16167****Specification**

---

**TNFRSF11B antibody - N-terminal region - Product Information**

Application	WB
Primary Accession	<a href="#">O00300</a>
Other Accession	<a href="#">NM_002546</a> , <a href="#">NP_002537</a>
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Horse, Dog
Predicted	Human, Mouse, Rat, Rabbit, Pig, Horse, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	46kDa kDa

**TNFRSF11B antibody - N-terminal region - Additional Information****Gene ID** 4982**Alias Symbol** OPG, TR1, OCIF**Other Names**

Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF11B, OCIF, OPG

**Format**

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

**Reconstitution & Storage**

Add 100 ul of distilled water. Final anti-TNFRSF11B antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

**Precautions**

TNFRSF11B antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

**TNFRSF11B antibody - N-terminal region - Protein Information****Name** TNFRSF11B**Synonyms** OCIF, OPG**Function**

Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for

TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

#### **Cellular Location**

Secreted.

#### **Tissue Location**


Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung

### **TNFRSF11B antibody - N-terminal region - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### **TNFRSF11B antibody - N-terminal region - Images**



WB Suggested Anti-TNFRSF11B Antibody Titration: 1.25µg/ml

ELISA Titer: 1:312500

Positive Control: HepG2 cell lysate

### **TNFRSF11B antibody - N-terminal region - Background**

Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

### **TNFRSF11B antibody - N-terminal region - References**

Simonet W.S., et al. Cell 89:309-319(1997).  
Yasuda H., et al. Endocrinology 139:1329-1337(1998).

Morinaga T.,et al.Eur. J. Biochem. 254:685-691(1998).

Ota T.,et al.Nat. Genet. 36:40-45(2004).

Suzuki Y.,et al.Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.